Hyundai ADM Bio (hereinafter referred to as Hyundai ADM) announced that it has recruited Dr. Dooyeon Cho, a rare clinical trial expert with a medical background in Korea, to strengthen its CRO business and begin full-scale development of cancer stem cell-targeting anticancer drugs (CSC-X).
The new Managing Director Cho Doo-yeon graduated from Yonsei University College of Medicine and received his doctorate in medicine from Ajou University College of Medicine. He served as a specialist in family medicine at Severance Hospital, a professor in the Department of Family Medicine at Ajou University Hospital, and the director of the Clinical Trial Center at Bundang CHA Hospital, accumulating extensive patient care experience. He did not settle for a hospital job, but served as the Vice President of DT&SanoMedics and the Director of the Medical Headquarters at JW Pharmaceutical, accumulating ample corporate experience as well.
Therefore, he emphasized that he is a true clinical trial expert who can provide customized CRO services that can satisfy the requests of both parties as he understands the positions of both the sponsor (pharmaceutical company) and the researcher (hospital) through his various experiences in hospitals, CROs, and pharmaceutical companies.
Executive Director Cho Doo-yeon has been appointed as the Head of the Medical Business Division at Hyundai ADM, and in his inaugural speech, he said, “I am very pleased to have joined Hyundai ADM, a domestic CRO company. Based on the experience I have accumulated at hospitals and companies, I will do my best to help Hyundai ADM rise to the ranks of the BIG 3 among domestic CRO companies in a short period of time. I also believe that I can provide great help in the development of anticancer drugs.”
- See more related articles
You must be logged in to post a comment.